ARTICLE | Company News
Max Delbrueck Center for Molecular Medicine Berlin-Buch, Wilex deal
September 26, 2016 7:00 AM UTC
The Max Delbrueck Center ( MDC) granted Wilex’s Heidelberg Pharma GmbH subsidiary an option to license humanized antibodies against tumor necrosis factor (TNF) receptor superfamily member 17 ( BCMA; ...